Found 66 results
Filters: Keyword is Humans and Author is Muyldermans, Serge  [Clear All Filters]
De Vos, J., N. Devoogdt, T. Lahoutte, and S. Muyldermans, "Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.", Expert Opin Biol Ther, vol. 13, issue 8, pp. 1149-60, 2013 Aug.
Behdani, M., S. Zeinali, M. Karimipour, H. Khanahmad, S. Schoonooghe, A. Aslemarz, N. Seyed, R. Moazami-Godarzi, F. Baniahmad, M. Habibi-Anbouhi, et al., "Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.", N Biotechnol, vol. 30, issue 2, pp. 205-9, 2013 Jan 25.
Hassanzadeh-Ghassabeh, G., N. Devoogdt, P. De Pauw, C. Vincke, and S. Muyldermans, "Nanobodies and their potential applications.", Nanomedicine (Lond), vol. 8, issue 6, pp. 1013-26, 2013 Jun.
De Genst, E., P-H. Chan, E. Pardon, S-T. D. Hsu, J. R. Kumita, J. Christodoulou, L. Menzer, D. Y. Chirgadze, C. V. Robinson, S. Muyldermans, et al., "A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.", J Phys Chem B, vol. 117, issue 42, pp. 13245-58, 2013 Oct 24.
Butler, J. E., N. Wertz, X-Z. Sun, J. K. Lunney, and S. Muyldermans, "Resolution of an immunodiagnostic dilemma: heavy chain chimeric antibodies for species in which plasmocytomas are unknown.", Mol Immunol, vol. 53, issue 1-2, pp. 140-8, 2013 Jan.
Xavier, C., I. Vaneycken, M. D'huyvetter, J. Heemskerk, M. Keyaerts, C. Vincke, N. Devoogdt, S. Muyldermans, T. Lahoutte, and V. Caveliers, "Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.", J Nucl Med, vol. 54, issue 5, pp. 776-84, 2013 May.
Habib, I., D. Smolarek, C. Hattab, M. Grodecka, G. Hassanzadeh-Ghassabeh, S. Muyldermans, S. Sagan, C. Gutiérrez, S. Laperche, C. Le-Van-Kim, et al., "V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays.", Anal Biochem, vol. 438, issue 1, pp. 82-9, 2013 Jul 1.
D'huyvetter, M., A. Aerts, C. Xavier, I. Vaneycken, N. Devoogdt, M. Gijs, N. Impens, S. Baatout, B. Ponsard, S. Muyldermans, et al., "Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.", Contrast Media Mol Imaging, vol. 7, issue 2, pp. 254-64, 2012 Mar-Apr.
Govaert, J., M. Pellis, N. Deschacht, C. Vincke, K. Conrath, S. Muyldermans, and D. Saerens, "Dual beneficial effect of interloop disulfide bond for single domain antibody fragments.", J Biol Chem, vol. 287, issue 3, pp. 1970-9, 2012 Jan 13.
Behdani, M., S. Zeinali, H. Khanahmad, M. Karimipour, N. Asadzadeh, K. Azadmanesh, A. Khabiri, S. Schoonooghe, M. Habibi Anbouhi, G. Hassanzadeh-Ghassabeh, et al., "Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.", Mol Immunol, vol. 50, issue 1-2, pp. 35-41, 2012 Feb.
Zhu, J., J. Declercq, B. Roucourt, G. H. Ghassabeh, S. Meulemans, J. Kinne, G. David, A. J. M. Vermorken, W. J. M. Van de Ven, I. Lindberg, et al., "Generation and characterization of non-competitive furin-inhibiting nanobodies.", Biochem J, vol. 448, issue 1, pp. 73-82, 2012 Nov 15.
Vincke, C., and S. Muyldermans, "Introduction to heavy chain antibodies and derived Nanobodies.", Methods Mol Biol, vol. 911, pp. 15-26, 2012.
Broisat, A., S. Hernot, J. Toczek, J. De Vos, L. M. Riou, S. Martin, M. Ahmadi, N. Thielens, U. Wernery, V. Caveliers, et al., "Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.", Circ Res, vol. 110, issue 7, pp. 927-37, 2012 Mar 30.
Gainkam, L. Olive Tcho, M. Keyaerts, V. Caveliers, N. Devoogdt, C. Vanhove, L. Van Grunsven, S. Muyldermans, and T. Lahoutte, "Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy.", Mol Imaging Biol, vol. 13, issue 5, pp. 940-8, 2011 Oct.
Ben Abderrazek, R., C. Vincke, I. Hmila, D. Saerens, N. Abidi, M. El Ayeb, S. Muyldermans, and B. Bouhaouala-Zahar, "Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin.", Protein Eng Des Sel, vol. 24, issue 9, pp. 727-35, 2011 Sep.
Stijlemans, B., G. Caljon, S. Kumar A. Natesan, D. Saerens, K. Conrath, D. Pérez-Morga, J. N. Skepper, A. Nikolaou, L. Brys, E. Pays, et al., "High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis.", PLoS Pathog, vol. 7, issue 6, pp. e1002072, 2011 Jun.
Bouhaouala-Zahar, B., R. Ben Abderrazek, I. Hmila, N. Abidi, S. Muyldermans, and M. El Ayeb, "Immunological aspects of scorpion toxins: current status and perspectives.", Inflamm Allergy Drug Targets, vol. 10, issue 5, pp. 358-68, 2011 Oct.
Vaneycken, I., N. Devoogdt, N. Van Gassen, C. Vincke, C. Xavier, U. Wernery, S. Muyldermans, T. Lahoutte, and V. Caveliers, "Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.", FASEB J, vol. 25, issue 7, pp. 2433-46, 2011 Jul.
Fernández, L. Ángel, and S. Muyldermans, "Recent developments in engineering and delivery of protein and antibody therapeutics.", Curr Opin Biotechnol, vol. 22, issue 6, pp. 839-42, 2011 Dec.